Supreme issues incentive stock options
Last month, Supreme Pharmaceuticals closed the third tranche of its previously announced financing for proceeds of $10,610,625 and aggregate proceeds from three tranches of $14,949,755. The company will use net proceeds of the Financing for the expansion of the company's hybrid greenhouse facility and for general working capital purposes.
"This financing represents a big step in the growth of Supreme," said John Fowler, CEO of Supreme. "We are well positioned to complete our Phase 1 expansion of the hybrid greenhouse to satisfy wholesale demand in excess of current capacity. The participation from existing shareholders, directors, management and local investors from Kincardine demonstrates our stakeholders' confidence in our organization and business plan. We are fortunate to have such a strong and supportive shareholder base moving forward."
For more information:
202 – 20 De Boers Dr, Toronto ON
Phone: (416) 630-7272